8-K: Kenvue Announces Q1 2024 Results and Restructuring Initiative

Kenvue reported a 1.1% increase in net sales for Q1 2024 and announced a multi-year restructuring plan to optimize costs.

Summary

• Kenvue's net sales for the first quarter of 2024 increased by 1.1% to $3.9 billion, with organic growth of 1.9%.
• The company's diluted earnings per share were $0.15, while adjusted diluted earnings per share reached $0.28.
• A multi-year restructuring initiative was approved, aiming for a 4% reduction in global workforce and $350 million in annualized pre-tax gross cost savings by 2026.
• Restructuring expenses are estimated at $275 million in both fiscal years 2024 and 2025, totaling approximately $550 million.
• The company expects to reinvest a portion of the cost savings into advertising, product promotion, and healthcare professional engagement.
• Kenvue reaffirmed its full-year 2024 outlook, projecting net sales growth between 1.0% and 3.0% and organic growth between 2.0% and 4.0%.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the restructuring plan aimed at improving efficiency and the reaffirmation of the 2024 outlook, but tempered by the restructuring costs and some volume contraction.

Positives

• Kenvue achieved a 1.1% increase in net sales and 1.9% organic growth in Q1 2024.
• The company saw a significant expansion in adjusted gross profit margin, reaching 60.2%.
• The restructuring initiative is expected to generate substantial cost savings of $350 million annually.
• Kenvue reaffirmed its full-year 2024 outlook, indicating confidence in future performance.
• The company plans to reinvest cost savings into growth opportunities, including advertising and product promotion.

Negatives

• The company experienced a volume contraction of 3.1% in Q1 2024, with two points attributed to retailer inventory adjustments.
• Operating income margin decreased to 14.1% due to a $68 million impairment charge and restructuring expenses.
• The effective tax rate increased to 30.7% due to jurisdictional mix of earnings and other factors.
• The company expects restructuring expenses of $275 million in both 2024 and 2025.

Risks

• The company may not be able to fully implement the restructuring initiative as designed.
• The estimated cost savings from the initiative may not be fully realized.
• The actual costs of the initiative may exceed the company's forecasts.
• The restructuring could cause disruptions to the company's business or operations.
• The company faces risks related to economic factors, competition, and supply chain issues.

Future Outlook

Kenvue reaffirmed its full-year 2024 outlook, expecting net sales growth between 1.0% and 3.0% and organic growth between 2.0% and 4.0%. The company also expects adjusted operating income margin to be slightly below 2023 and adjusted diluted earnings per share to be in the range of $1.10 $1.20.

Management Comments

• Thibaut Mongon, Chief Executive Officer, stated that the company began executing against strategic priorities in Q1 2024, enabling a solid start to the year.
• Paul Ruh, Chief Financial Officer, mentioned that the restructuring initiatives will structurally position Kenvue for success and create long-term shareholder value.

Industry Context

Kenvue's performance is being evaluated in the context of the broader consumer health industry, where companies are focusing on efficiency and growth. The restructuring initiative reflects a trend of companies optimizing their cost structures to improve profitability and competitiveness.

Comparison to Industry Standards

• Kenvue's organic growth of 1.9% is moderate compared to some competitors in the consumer health sector, which have seen higher growth rates in certain segments.
• The adjusted gross profit margin of 60.2% is competitive, indicating effective cost management and pricing strategies.
• The restructuring initiative, with a 4% workforce reduction, is a significant move, similar to actions taken by other large consumer goods companies to streamline operations.
• The projected $350 million in annualized cost savings is substantial and could improve Kenvue's profitability compared to peers.
• Kenvue's reaffirmed outlook for 2024 is in line with expectations for the sector, but the company will need to execute well to achieve these targets.

Stakeholder Impact

• Shareholders may see long-term value creation from the restructuring and cost savings.
• Employees will be impacted by the 4% workforce reduction.
• Customers may benefit from reinvestments in product promotion and innovation.
• Suppliers may see changes in procurement as the company optimizes its operations.

Next Steps

• Kenvue will continue to implement its multi-year restructuring initiative.
• The company will focus on reinvesting cost savings into growth opportunities.
• Kenvue will continue to execute its strategic priorities to reach more consumers and enhance organizational efficiencies.

Key Dates

Keywords

Kenvue, restructuring, cost savings, net sales, organic growth, earnings per share, consumer health, financial results, Q1 2024, operating margin